The Association between Mushroom Consumption and Mild Cognitive Impairment: A Community-Based Cross-Sectional Study in Singapore (2019)

2023-02-27

Journal of Alzheimer’s Disease 68 (2019) 197–203

Abstract

We examined the cross-sectional association between mushroom intake and mild cognitive impairment (MCI) using data from 663 participants aged 60 and above from the Diet and Healthy Aging (DaHA) study in Singapore. Compared with participants who consumed mushrooms less than once per week, participants who consumed mushrooms >2 portions per week had reduced odds of having MCI (odds ratio = 0.43, 95% CI 0.23–0.78, p = 0.006) and this association was independent of age, gender, education, cigarette smoking, alcohol consumption, hypertension, diabetes, heart disease, stroke, physical activities, and social activities. Our cross-sectional data support the potential role of mushrooms and their bioactive compounds in delaying neurodegeneration.

Source: https://www.naturalhealthresearch.org/wp-content/uploads/2019/04/Mushroom-Consumption-Delays-Mild-Cognitive-Impairment.pdf

Improving Effects of the Mushroom Yamabushitake (Hericium erinaceus) on Mild Cognitive Impairment: A Double-blind Placebo-controlled Clinical Trial (2009)

A double-blind, parallel-group, placebo-controlled trial was conducted in Japanese men and women aged 50-80 years who were diagnosed with mild cognitive impairment using a cognitive function scale based on the revised Hasegawa Dementia Scale (HDS-R) to examine the effect of oral consumption of erinaceus erinaceus on improving cognitive impairment.

A Randomized, Double-Blind and Placebo-Controlled Study of a Ganoderma lucidum Polysaccharide Extract in Neurasthenia (2005)

Ganoderma lucidum has been widely used to treat various diseases, including cancer, diabetes, and neurasthenia in many Asian countries.